172 related articles for article (PubMed ID: 37583267)
1. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
[TBL] [Abstract][Full Text] [Related]
2. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
4. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
de Nigris E; Treharne C; Brighton N; Holmgren U; Walker A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2022; 17():2987-3000. PubMed ID: 36444374
[TBL] [Abstract][Full Text] [Related]
6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
7. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
[No Abstract] [Full Text] [Related]
8. Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging.
Usmani O; Li G; De Backer J; Sadafi H; Wu L; Marshall J
Respir Res; 2023 Sep; 24(1):226. PubMed ID: 37742015
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
10. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
Rabe KF; Martinez FJ; Singh D; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
Ther Adv Respir Dis; 2021; 15():17534666211034329. PubMed ID: 34428980
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
12. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
13. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Bourdin A; Criner G; Devouassoux G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kalhan R; Lange P; Lettis S; Lipson DA; Lomas DA; Echave-Sustaeta María-Tomé JM; Martin N; Martinez FJ; Quasny H; Sail L; Siler TM; Singh D; Thomashow B; Watz H; Wise R; Hanania NA
Chronic Obstr Pulm Dis; 2021 Jan; 8(1):76-90. PubMed ID: 33156982
[TBL] [Abstract][Full Text] [Related]
14. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
15. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
18. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
[TBL] [Abstract][Full Text] [Related]
19. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
Respir Med; 2019; 158():59-66. PubMed ID: 31605923
[TBL] [Abstract][Full Text] [Related]
20. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA; Crim C; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Lettis S; Manchester P; Martin N; Midwinter D; Morris A; Pascoe SJ; Singh D; Wise RA; Martinez FJ
Am J Respir Crit Care Med; 2020 Jun; 201(12):1508-1516. PubMed ID: 32162970
[No Abstract] [Full Text] [Related]
[Next] [New Search]